PYRAMID BIOSCIENCES
Pyramid Biosciences is dedicated to discovering and developing targeted therapeutics for a wide range of disorders that are regulated by the tropomyosin receptor kinase (TRK) family. By precisely and selectively modulating the actions of these fundamental cell surface receptors, we can control the key signaling pathways responsible for a patient’s disease, condition, or symptoms.
PYRAMID BIOSCIENCES
Social Links:
Industry:
Biotechnology Life Science
Founded:
2015-01-01
Address:
Needham, Massachusetts, United States
Country:
United States
Website Url:
http://www.pyramidbio.com
Total Employee:
1+
Status:
Active
Contact:
(502) 589-5400
Email Addresses:
[email protected]
Total Funding:
61.56 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Google Analytics LetsEncrypt Apple Mobile Web Clips Icon WordPress Google Universal Analytics
Similar Organizations
Axcella
Axcella is a biotechnology company that treats diseases using endogenous metabolic modulators.
Biotech Holdings
Biotech Holdings is a provider of biotechnology service.
Cyagen Biosciences
Cyagen Biosciences is an emerging and innovative biotechnology company.
hC Bioscience
hC Bioscience is an innovator and pioneer of protein editing using context agnostic engineered tRNA.
Pulmair Medical
Pulmair Medical is a provider of biotechnology services.
Strand Life Sciences - Bioinformatics
Strand Life Sciences - Bioinformatics is a provider of bioinformatics services.
Themis Bioscience
Themis Bioscience is a start-up biotechnology company.
Current Advisors List
Current Employees Featured
Founder
Investors List
Prospect Hill Growth Partners
Prospect Hill Growth Partners investment in Series B - Pyramid Biosciences
Oracle Investment Management Inc.
Oracle Investment Management Inc. investment in Series B - Pyramid Biosciences
Adage Capital Management
Adage Capital Management investment in Series B - Pyramid Biosciences
Averill Master Fund
Averill Master Fund investment in Series B - Pyramid Biosciences
Adage Capital Management
Adage Capital Management investment in Venture Round - Pyramid Biosciences
Averill Master Fund
Averill Master Fund investment in Venture Round - Pyramid Biosciences
Prospect Hill Growth Partners
Prospect Hill Growth Partners investment in Venture Round - Pyramid Biosciences
Alpine Meridian
Alpine Meridian investment in Seed Round - Pyramid Biosciences
Boston Harbor Angels
Boston Harbor Angels investment in Angel Round - Pyramid Biosciences
Key Employee Changes
Official Site Inspections
http://www.pyramidbio.com Semrush global rank: 4.83 M Semrush visits lastest month: 1.86 K
Unable to get host informations!!!
More informations about "Pyramid Biosciences"
Pyramid Biosciences - Crunchbase Company Profile & Funding
Contact Email [email protected] Phone Number (502) 589-5400 Pyramid Biosciences is dedicated to discovering and developing targeted therapeutics for a wide range of disorders …See details»
Pyramid Biosciences - Overview, News & Similar companies
Pyramid Biosciences to Present at the 2022 Jefferies London Healthcare Conference WALTHAM, Mass.--(BUSINESS WIRE)-- #PyramidBiosciences--Pyramid Biosciences, Inc., a privately …See details»
Pyramid Biosciences Expands Precision Oncology Pipeline - PR …
Nov 16, 2021 For more information, please visit www.pyramidbio.com. Media Inquiries: McDougall Communications on behalf of Pyramid Biosciences Elizabeth Harness, +1-585-435 …See details»
Pyramid Biosciences Announces Leadership Team Expansion
Apr 14, 2021 For more information, please visit www.pyramidbio.com. Contacts Media Inquiries: McDougall Communications on behalf of Pyramid Biosciences Elizabeth Harness, +1-585-435 …See details»
Pyramid Biosciences Names Biren Amin as Chief Financial and …
Sep 7, 2022 For more information, please visit: www.pyramidbio.com Contacts Pyramid Biosciences Media Inquiries: McDougall Communications on behalf of Pyramid Biosciences …See details»
Pyramid Biosciences Expands Oncology Pipeline with In-Licensing …
Apr 13, 2023 For more information, please visit www.pyramidbio.com. Pyramid Biosciences Media Inquiries: McDougall Communications on behalf of Pyramid Biosciences [email protected]See details»
Pyramid Biosciences Receives Orphan Drug Designation for PBI …
Jul 6, 2022 Pyramid Biosciences Investor Inquiries: Jordan Leef, Pyramid Biosciences COO, CFO and Co-Founder, +1-781-530-4461 [email protected] Release Summary Pyramid …See details»
Pyramid Biosciences Announces Leadership Team Expansion
Apr 14, 2021 Investor Inquiries: Jordan Leef, Pyramid Biosciences, CBO, CFO and Co-Founder +1-781-530-4461, [email protected] Source: Pyramid Biosciences Inc. In This StorySee details»
Pyramid Biosciences Names Nushmia Khokhar, MD, as Chief
Aug 8, 2022 WALTHAM, Mass.--(BUSINESS WIRE)-- Pyramid Biosciences, Inc., a Boston-based, clinical-stage biotechnology company focused on developing new and highly …See details»
Pyramid Biosciences Announces Exclusive Global License of …
WALTHAM, Mass., Dec. 17, 2018 /PRNewswire/ -- Pyramid Biosciences, Inc. (www.pyramidbio.com), a Boston-based biotechnology company developing new therapies …See details»
Pyramid Biosciences Secures $28 Million in Funding to Accelerate ...
Aug 31, 2020 For more information, please visit www.pyramidbio.com. Contacts. Media Inquiries McDougall Communications on behalf of Pyramid Biosciences Elizabeth Harness, +1-585-435 …See details»
Pyramid Bio bets $1B on oncology ADC | Pharma Manufacturing
Apr 14, 2023 Pyramid Biosciences has signed a deal with China-based GeneQuantum Healthcare to develop and commercialize a potential best-in-class antibody-drug conjugate …See details»
Pyramid Biosciences Expands Oncology Pipeline with In-Licensing …
Apr 14, 2023 Pyramid’s lead oncology program PBI-200, a highly CNS penetrant next-generation NTRK inhibitor is currently in a global Phase 1/2 clinical trial in patients with NTRK …See details»
Pyramid Biosciences Appoints Brian Lestini, MD, PhD as Chief …
Jan 10, 2022 For more information, please visit www.pyramidbio.com. Contacts Media Inquiries: McDougall Communications on behalf of Pyramid Biosciences Elizabeth Harness, +1-585-435 …See details»
Pyramid deviates from TRK with deal for rival to Gilead ADC
Apr 13, 2023 Gilead paid $21 billion to buy Immunomedics for the first-in-class, TROP2-directed ADC Trodelvy in 2020. Sales of the drug increased (PDF) 79% last year, climbing to $680 …See details»
Pyramid Biosciences Announces TIME Trial™ Program …
Apr 12, 2022 For more information, please visit: www.pyramidbio.com. Pyramid Biosciences Media Inquiries: McDougall Communications on behalf of Pyramid Biosciences Elizabeth …See details»
Pyramid Biosciences and GeneQuantum Healthcare Announce …
Apr 18, 2023 For more information, please visit www.pyramidbio.com. Pyramid Biosciences Media Inquiries: McDougall Communications on behalf of Pyramid Biosciences Laura DiCaprio …See details»
Pyramid Biosciences Announces Initial Closing of Series B …
Oct 27, 2021 For more information, please visit www.pyramidbio.com. Contacts. Media Inquiries. McDougall Communications on behalf of Pyramid Biosciences Elizabeth Harness, +1-585-435 …See details»
Pyramid Biosciences Announces First Patients Dosed in Phase 1 …
May 20, 2021 For more information, please visit www.pyramidbio.com. Contacts. Media Inquiries: McDougall Communications on behalf of Pyramid Biosciences Elizabeth Harness, …See details»
Pyramid Biosciences and Caris Life Sciences Announce MI Trials ...
Mar 10, 2022 WALTHAM, Mass. and IRVING, Texas, March 10, 2022 /PRNewswire/ -- Pyramid Biosciences, Inc., and Caris Life Sciences ® (Caris), today announced a collaboration to …See details»